ReviewContinuum (Minneapolis, Minn.)2013
Alzheimer disease pharmacologic treatment and treatment research.
Review in Continuum (Minneapolis, Minn.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Combining drug and music therapy in patients with moderate Alzheimer's disease: a randomized study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Trial
- Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase AMolecular imaging and biology · 2017Trial
- Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers .International journal of clinical pharmacology and therapeutics · 2016Trial
- Review
- Article
- Article
- Article
- Pro-neurogenic, Memory-Enhancing and Anti-stress Effects of DF302, a Novel Fluorine Gamma-Carboline Derivative with Multi-target Mechanism of Action.Molecular neurobiology · 2018Article
- Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [(18)F]-Florbetaben PET Quantitation in Alzheimer's Model Mice.Frontiers in neuroscience · 2016Article
- Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist.Pharmacology research & perspectives · 2015Review
- Drug therapies in older adults (part 1).Clinical medicine (London, England) · 2015Review
- Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models.PloS one · 2015Article
- Evidences for B6C3-Tg (APPswe/PSEN1dE9) double-transgenic mice between 3 and 10 months as an age-related Alzheimer's disease model.Journal of molecular neuroscience : MN · 2014Article
- Modifiable risk factors for Alzheimer disease and subjective memory impairment across age groups.PloS one · 2014Article
- Ginger components as new leads for the design and development of novel multi-targeted anti-Alzheimer's drugs: a computational investigation.Drug design, development and therapy · 2014Article
- Posterior cortical atrophy: review of the recent literature.Current neurology and neuroscience reports · 2013Review
- Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics.Current translational geriatrics and experimental gerontology reports · 2013Article
- Undifferentiated and differentiated PC12 cells protected by huprines against injury induced by hydrogen peroxide.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis article reviews marketed pharmacologic treatments for Alzheimer disease as well as their efficacy, effectiveness, adverse effects, and issues involved in their use, including duration of treatment, adverse events, and controversies. Current experimental drug development, including challenges to developing successful drugs for Alzheimer disease, are also reviewed and assessed. RECENT
findingsCholinesterase inhibitors and memantine are the available pharmacologic treatment options. They show limited clinical effects over the shorter term for some patients, mild to moderate cholinergic adverse effects in a minority of patients, and potentially underappreciated toxicity over the longer term. No subsequent experimental drug in development has been successful thus far; there has not been a new drug marketed for Alzheimer disease since 2003. SUMMARY: Cholinesterase inhibitors and memantine are marketed for the treatment of Alzheimer disease. Drug development programs aimed at new targets, including the amyloid-β cascade, have been unsuccessful thus far despite their designs to detect very small or minimal clinical effects from the experimental drugs. Marked advances in preclinical science nevertheless support a basis for considerable optimism that effective interventions will be found soon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.